References
- Purvin VA. Optic neuropathies for the neurologist. Semin Neurol 2000;20:97–110
- Arnold CA. Ischemic optic neuropathy, diabetic papillopathy and papillophlebitis. In: Yanoff M, Duker JS, editors. Ophthalmology. London: Mosby International; 1999:11/7.5–11/7.6
- Chang Y, Wu W. Intravitreal triamcinolone acetonite for the management of papillophlebitis and associated macular edema. Int Ophthalmol 2008;28:291–296
- Heier JS, Morley MG. Venous obstructive disease of the retina. In: Yanoff M, Duker JS, editors. Ophthalmology. London: Mosby International; 1999:8/18.1-8/18.8
- Appen RE. Optic disc edema. In: Levin LA, Arnold AC, editors. Neuroophthalmology. New York: Thieme Medical Publishers; 2005:101--112
- Noma H, Shimizu H, Mimura T. Unilateral macular edema with central retinal vein occlusion in systemic lupus erythematosus: a case report. Clin Ophthalmol 2013;7:865–867
- Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 2013;1:CD009510. doi: 1002/14651858.CD009510.pub2
- Demir M, Dirim B, Acar Z, Sendul Y, Oba E. Comparison of the effects of intravitreal bevacizumab and triamcinolonacetonide in the treatment of macular edema secondary to central retinal vein occlusion. Indian J Ophthalmol 2014;62:279–283
- Daien V, Navarre S, Fessler P, Vergely L, Villain M, Schneider C. Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion. Eur J Ophthalmol 2012;22:1013–1018
- Niederhauser N, Valmaggia C. Bevacizumab and ranibizumab for macular edema due to retinal vein occlusions. Klin Monbl Augenheilkd 2013;230:405–408